Administration of a determinant of preproinsulin can induce regulatory T cells and suppress anti-islet autoimmunity in NOD mice

Clinical Immunology

Volumn 136, Issue 1, 2010, Pages 74-82

  Arai, Takashi ^a   Moriyama, Hiroaki ^a   Shimizu, Mami ^a   Sasaki, Hirotomo ^a   Kishi, Minoru ^a   Okumachi, Yasuyo ^a   Yasuda, Hisafumi ^a   Hara, Kenta ^a   Yokono, Koichi ^a   Nagata, Masao ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Diabetes; Immunotherapy; Insulin; Leader peptide; NOD; Regulatory T cell

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 4; PREPROINSULIN; PREPROINSULIN 1; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; BINDING AFFINITY; CELL ISOLATION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG PROTEIN BINDING; FEMALE; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; REGULATORY T LYMPHOCYTE; SPLEEN; SPLEEN CELL;

AMINO ACID SEQUENCE; ANIMALS; AUTOIMMUNITY; BLOOD GLUCOSE; CELL COUNT; CONCANAVALIN A; DIABETES MELLITUS, TYPE 1; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNOTHERAPY, ACTIVE; INSULIN; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-4; ISLETS OF LANGERHANS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED NOD; MICE, KNOCKOUT; PEPTIDE FRAGMENTS; PROTEIN BINDING; PROTEIN PRECURSORS; SPLEEN; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; TH2 CELLS; TRANSFORMING GROWTH FACTOR BETA; VACCINATION;

EID: 77951986069     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2010.02.016     Document Type: Article

References (33)

1. Eisenbarth G.S. Type I diabetes mellitus. A chronic autoimmune disease. N. Engl. J. Med. 314 (1986) 1360-1368
2. J. Dupre, C.R. Stiller, M. Gent, A. Donner, B. von Graffenried, D. Heinrichs, M. Jenner, P. Keown, J. Mahon, R. Martell, Clinical trials of cyclosporin in IDDM, Diabetes Care. 11 Suppl 1:37-44. (1988) 37-44.
3. Lipton R., LaPorte R.E., Becker D.J., Dorman J.S., Orchard T.J., Atchison J., and Drash A.L. Cyclosporin therapy for prevention and cure of IDDM. Epidemiological perspective of benefits and risks. Diabetes Care 13 (1990) 776-784
4. Herold K.C., Hagopian W., Auger J.A., Poumian-Ruiz E., Taylor L., Donaldson D., Gitelman S.E., Harlan D.M., Xu D., Zivin R.A., and Bluestone J.A. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346 (2002) 1692-1698
5. Herold K.C., Gitelman S.E., Masharani U., Hagopian W., Bisikirska B., Donaldson D., Rother K., Diamond B., Harlan D.M., and Bluestone J.A. A single course of anti-CD3 monoclonal antibody hOKT3{gamma}1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54 (2005) 1763-1769
6. Ludvigsson J., Faresjo M., Hjorth M., Axelsson S., Cheramy M., Pihl M., Vaarala O., Forsander G., Ivarsson S., Johansson C., Lindh A., Nilsson N.O., Aman J., Ortqvist E., Zerhouni P., and Casas R. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N. Engl. J. Med. 359 (2008) 1909-1920
7. Moriyama H., Abiru N., Paronen J., Sikora K., Liu E., Miao D., Devendra D., Beilke J., Gianani R., Gill R.G., and Eisenbarth G.S. Evidence for a primary islet autoantigen (preproinsulin 1) for insulitis and diabetes in the nonobese diabetic mouse. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 10376-10381
8. Moriyama H., Nagata M., Arai T., Okumachi Y., Yamada K., Kotani R., Yasuda H., Hara K., and Yokono K. Insulin as a T cell antigen in type 1 diabetes supported by the evidence from the insulin knockout NOD mice. Diabetes Res. Clin. Pract. 77 (2007) S155-S160
9. Nakayama M., Abiru N., Moriyama H., Babaya N., Liu E., Miao D., Yu L., Wegmann D.R., Hutton J.C., Elliott J.F., and Eisenbarth G.S. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 435 (2005) 220-223
10. Nanto-Salonen K., Kupila A., Simell S., Siljander H., Salonsaari T., Hekkala A., Korhonen S., Erkkola R., Sipila J.I., Haavisto L., Siltala M., Tuominen J., Hakalax J., Hyoty H., Ilonen J., Veijola R., Simell T., Knip M., and Simell O. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 372 (2008) 1746-1755
11. Diabetes P.T.-T. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N. Engl. J. Med. 346 (2002) 1685-1691
12. Suri A., Walters J.J., Gross M.L., and Unanue E.R. Natural peptides selected by diabetogenic DQ8 and murine I-A(g7) molecules show common sequence specificity. J Clin. Invest. 115 (2005) 2268-2276
13. Nagata M., Yokono K., Hayakawa M., Kawase Y., Hatamori N., Ogawa W., Yonezawa K., Shii K., and Baba S. Destruction of pancreatic islet cells by cytotoxic T lymphocytes in nonobese diabetic mice. J. Immunol. 143 (1989) 1155-1162
14. Kotani R., Nagata M., Moriyama H., Nakayama M., Yamada K., Chowdhury S.A., Chakrabarty S., Jin Z., Yasuda H., and Yokono K. Detection of GAD65-reactive T-cells in type 1 diabetes by immunoglobulin-free ELISPOT assays. Diabetes Care 25 (2002) 1390-1397
15. Kotani R., Nagata M., Imagawa A., Moriyama H., Yasuda H., Miyagawa J., Hanafusa T., and Yokono K. T lymphocyte response against pancreatic beta cell antigens in fulminant Type 1 diabetes. Diabetologia 47 (2004) 1285-1291
16. Sakaguchi S. Naturally arising Foxp3-expressing CD25 + CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 6 (2005) 345-352
17. Q. Tang, J.A. Bluestone, Regulatory T-cell physiology and application to treat autoimmunity, Immunol. Rev. 212:217-37. (2006) 217-237.
18. Ludvigsson J. Therapy with GAD in diabetes. Diabetes Metab. Res. Rev. 25 (2009) 307-315
19. Agardh C.D., Lynch K.F., Palmer M., Link K., and Lernmark A. GAD65 vaccination: 5 years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes. Diabetologia 52 (2009) 1363-1368
20. Daniel D., and Wegmann D.R. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). PNAS 93 (1996) 956-960
21. Muir A., Peck A., Clare-Salzler M., Song Y.H., Cornelius J., Luchetta R., Krischer J., and Maclaren N. Insulin immunization of nonobese diabetic mice induces a protective insulitis characterized by diminished intraislet interferon-gamma transcription. J. Clin. Invest. 95 (1995) 628-634
22. Zhang Z.J., Davidson L., Eisenbarth G., and Weiner H.L. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 10252-10256
23. Skyler J.S., Krischer J.P., Wolfsdorf J., Cowie C., Palmer J.P., Greenbaum C., Cuthbertson D., Rafkin-Mervis L.E., Chase H.P., and Leschek E. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial-Type 1. Diabetes Care 28 (2005) 1068-1076
24. Zhang L., Nakayama M., and Eisenbarth G.S. Insulin as an autoantigen in NOD/human diabetes. Curr. Opin. Immunol. 20 (2008) 111-118
25. Sadelain M.W., Qin H.Y., Lauzon J., and Singh B. Prevention of type I diabetes in NOD mice by adjuvant immunotherapy. Diabetes 39 (1990) 583-589
26. Liddi R., Beales P.E., Rosignoli G., and Pozzilli P. Incomplete Freund's adjuvant reduces diabetes in the non-obese diabetic mouse. Horm. Metab. Res. 32 (2000) 201-206
27. Halbout P., Briand J.P., Becourt C., Muller S., and Boitard C. T cell response to preproinsulin I and II in the nonobese diabetic mouse. J. Immunol. 169 (2002) 2436-2443
28. Levisetti M.G., Lewis D.M., Suri A., and Unanue E.R. Weak proinsulin peptide-major histocompatibility complexes are targeted in autoimmune diabetes in mice. Diabetes 57 (2008) 1852-1860
29. Levisetti M.G., Suri A., Petzold S.J., and Unanue E.R. The insulin-specific T cells of nonobese diabetic mice recognize a weak MHC-binding segment in more than one form. J. Immunol. 178 (2007) 6051-6057
30. Suri A., Levisetti M.G., and Unanue E.R. Do the peptide-binding properties of diabetogenic class II molecules explain autoreactivity?. Curr. Opin. Immunol. 20 (2008) 105-110
31. James E.A., and Kwok W.W. Low-affinity major histocompatibility complex-binding peptides in type 1 diabetes. Diabetes 57 (2008) 1788-1789
32. Bresson D., Togher L., Rodrigo E., Chen Y., Bluestone J.A., Herold K.C., and von Herrath M. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J. Clin. Invest. 116 (2006) 1371-1381
33. Skowera A., Ellis R.J., Varela-Calvino R., Arif S., Huang G.C., Van Krinks C., Zaremba A., Rackham C., Allen J.S., Tree T.I., Zhao M., Dayan C.M., Sewell A.K., Unger W., Drijfhout J.W., Ossendorp F., Roep B.O., and Peakman M. CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J Clin. Invest. 118 (2008) 3390-3402